Overview
Carney triad is an extremely rare syndrome characterized by the co-occurrence of three distinct tumor types: gastrointestinal stromal tumors (GISTs), pulmonary chondromas (benign cartilaginous tumors of the lung), and extra-adrenal paragangliomas (tumors arising from neural crest-derived cells). First described by J. Aidan Carney in 1977, the condition predominantly affects young women, with most cases presenting before the age of 35. The complete triad (all three tumor types) is present in only a minority of patients; most individuals develop two of the three tumors. Carney triad is distinct from Carney-Stratakis syndrome (dyad), which involves only GISTs and paragangliomas and has a known germline succinate dehydrogenase (SDH) subunit mutation with autosomal dominant inheritance. The body systems primarily affected include the gastrointestinal tract (most commonly the stomach, where GISTs cause bleeding, pain, or obstruction), the lungs (where chondromas are often discovered incidentally on imaging), and the autonomic nervous system (where paragangliomas may be functional, producing catecholamines and causing hypertension, palpitations, and sweating). Additional associated findings may include esophageal leiomyoma and adrenocortical adenoma. GISTs in Carney triad tend to be multifocal and may recur or metastasize, particularly to the liver and lymph nodes, though the clinical course is often indolent compared to sporadic GISTs. The etiology of Carney triad remains largely unknown. Unlike Carney-Stratakis syndrome, most cases of Carney triad are sporadic and do not follow a clear Mendelian inheritance pattern, though epigenetic alterations such as hypermethylation of the SDHC gene promoter have been identified in tumor tissue. Treatment is primarily surgical, involving resection of symptomatic or growing tumors. Imatinib and other tyrosine kinase inhibitors used for sporadic GISTs have shown limited efficacy in Carney triad-associated GISTs, which are typically wild-type for KIT and PDGFRA mutations. Long-term surveillance is essential due to the risk of metachronous tumor development and recurrence over many years.
Clinical phenotype terms— hover any for plain English:
Sporadic
Usually appears on its own, not inherited from a parent
Childhood to adulthood
Can begin any time from childhood through adulthood
Treatments
No FDA-approved treatments are currently listed for Carney triad.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Carney triad at this time.
New trials open frequently. Follow this disease to get notified.
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Carney triad.
Community
No community posts yet. Be the first to share your experience with Carney triad.
Start the conversation →Latest news about Carney triad
No recent news articles for Carney triad.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Carney triad
What is Carney triad?
Carney triad is an extremely rare syndrome characterized by the co-occurrence of three distinct tumor types: gastrointestinal stromal tumors (GISTs), pulmonary chondromas (benign cartilaginous tumors of the lung), and extra-adrenal paragangliomas (tumors arising from neural crest-derived cells). First described by J. Aidan Carney in 1977, the condition predominantly affects young women, with most cases presenting before the age of 35. The complete triad (all three tumor types) is present in only a minority of patients; most individuals develop two of the three tumors. Carney triad is distinct
How is Carney triad inherited?
Carney triad follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Carney triad typically begin?
Typical onset of Carney triad is childhood to adulthood. Age of onset can vary across affected individuals.
Which specialists treat Carney triad?
1 specialists and care centers treating Carney triad are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.